InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,728.80
(
0.41%
)
US TECH 100
19,531.20
(
0.17%
)
Dow Jones
42,052.19
(
0.69%
)
Brent Oil
75.13
(
1.42%
)
Bitcoin
68,725.95
(
-0.02%
)
Post# of 97239
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

bra1loga

Send PM Follow Ignore
Followers 384
Posts 8154
Boards Moderated 7
Alias Born 07/15/2007

bra1loga

Re: None

Saturday, 02/08/2014 5:31:58 PM

Saturday, February 08, 2014 5:31:58 PM

Post# of 97239
Avanir Pharmaceutical Inc. (NASDAQ: AVNR) is a name with real upside to buy at Piper Jaffray. Shares of the company rose last week after the company said sales of its drug Nuedexta were strong in the fiscal first quarter. Avanir said it expects to report between $23.3 million and $23.9 million in net sales of Nuedexta. According to FactSet, analysts expected $22.7 million on average. The analyst also think the company will prevail in its current litigation involving the drug. The Piper Jaffray price target is $13. The Thomson/First Call estimate is $8.19. Avanir closed Friday at $3.44. A move to the target would be more than a 300% gain.

Exchange Personmarks?

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up